Form 4: Inovio Pharmaceuticals CEO Reports Stock Transactions
SEC Form 4 Filing
Jacqueline E. Shea, CEO of Inovio Pharmaceuticals, reports the vesting and settlement of restricted stock units, along with associated tax withholding.
Summary
- Jacqueline E. Shea, the CEO of Inovio Pharmaceuticals, filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
- On May 15, 2025, 17,744 restricted stock units vested and were settled, resulting in the acquisition of 17,744 shares of common stock.
- Additionally, 7,717 shares were withheld by the issuer to cover tax obligations related to the vesting of these restricted stock units at a price of $1.95 per share.
- Following these transactions, Shea directly owns 59,685 shares of Inovio Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions related to executive compensation, with no indication of positive or negative sentiment.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track executive compensation and ownership changes.
Stakeholder Impact
- Shareholders may be interested in tracking executive compensation and ownership changes.
Key Dates
| Date | Description |
|---|---|
| 05/15/2024 | 17,745 restricted stock units vested. |
| 05/15/2025 | 17,744 restricted stock units vested and settled; tax withholding occurred. |
| 05/16/2025 | Date of the report filing. |
| 05/15/2026 | 17,744 restricted stock units will vest. |
Keywords
Form 4, Beneficial Ownership, INO, Inovio Pharmaceuticals, Jacqueline E. Shea, Restricted Stock Units, Stock Transactions, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.